InventisBio, Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

InventisBio, Co., Ltd.

Why is InventisBio, Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 25.00% and Operating profit at -198.36% over the last 5 years

Positive results in Mar 25

NET PROFIT(HY) At CNY 6.6 MM has Grown at 105.25%
OPERATING CASH FLOW(Y) Highest at CNY -193.12 MM
NET SALES(HY) Higher at CNY 157.76 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 123.42%, its profits have risen by 15%

Market Beating Performance

The stock has generated a return of 123.42% in the last 1 year, much higher than market (China Shanghai Composite) returns of 12.95%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to InventisBio, Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is InventisBio, Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

InventisBio, Co., Ltd.

115.13%

3.52

74.10%

China Shanghai Composite

15.14%

0.89

14.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

25.00%

EBIT Growth (5y)

-198.36%

EBIT to Interest (avg)

-276.45

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.92

Sales to Capital Employed (avg)

0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.61

EV to EBIT

-59.91

EV to EBITDA

-65.80

EV to Capital Employed

80.58

EV to Sales

66.49

PEG Ratio

Dividend Yield

ROCE (Latest)

-134.51%

ROE (Latest)

-8.58%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company

NET PROFIT(HY)

At CNY 6.6 MM has Grown at 105.25%

OPERATING CASH FLOW(Y)

Highest at CNY -193.12 MM

NET SALES(HY)

Higher at CNY 157.76 MM

ROCE(HY)

Highest at -11.58%

RAW MATERIAL COST(Y)

Fallen by -2,654.82% (YoY

-6What is not working for the Company

INTEREST(9M)

At CNY 0.66 MM has Grown at 142.8%

DEBT-EQUITY RATIO (HY)

Highest at -90.94 %

Here's what is working for InventisBio, Co., Ltd.

Net Sales

At CNY 157.76 MM has Grown at 135.79%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (CNY MM)

Net Profit

At CNY 6.6 MM has Grown at 105.25%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales

Higher at CNY 157.76 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (CNY MM)

Net Profit

Higher at CNY 6.6 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Operating Cash Flow

Highest at CNY -193.12 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Raw Material Cost

Fallen by -2,654.82% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for InventisBio, Co., Ltd.

Interest

At CNY 0.66 MM has Grown at 142.8%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -90.94 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio